Hot off the Forge
-
“I’m honored to be presenting alongside a lineup of industry leaders and to share the groundbreaking progress that Forge Biologics…
-
Forge is now actively recruiting patients for enrollment in the RESKUE phase 1/2 clinical trial of FBX-101.
-
Forge to initiate a Phase 1/2 clinical trial evaluating its novel, first-in-human AAV gene therapy, FBX-101, for patients with Krabbe…
-
Expansion of the leadership team to strengthen expertise in AAV manufacturing, regulatory affairs, and financial operations.
-
Forge will use the proceeds to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021.